{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Hutchmed",
    "query": {
      "sponsor": "Hutchmed"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Hutchmed&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T13:31:22.513Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05602597",
      "title": "HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Lymphoma"
      ],
      "interventions": [
        {
          "name": "Itraconazole 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Rifampin 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-06-01",
      "completion_date": "2022-08-06",
      "has_results": false,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05602597"
    },
    {
      "nct_id": "NCT04322539",
      "title": "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer",
        "Metastatic Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchison Medipharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 691,
      "start_date": "2020-08-12",
      "completion_date": "2024-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322539"
    },
    {
      "nct_id": "NCT04577963",
      "title": "A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Endometrial Cancer",
        "Solid Tumor, Unspecified, Adult",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-08-09",
      "completion_date": "2024-06-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04577963"
    },
    {
      "nct_id": "NCT04814732",
      "title": "Expanded Access Program of Surufatinib",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Surufatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-04-12",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 11,
      "location_summary": "Denver, Colorado • Baltimore, Maryland • Detroit, Michigan + 8 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Florham Park",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04814732"
    },
    {
      "nct_id": "NCT04372407",
      "title": "A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Surufatinib",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchison Medipharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2020-07-09",
      "completion_date": "2021-01-19",
      "has_results": false,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372407"
    },
    {
      "nct_id": "NCT04557397",
      "title": "Fruquintinib CYP3A Inhibitor and Inducer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Drug Interaction"
      ],
      "interventions": [
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchison Medipharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-09-02",
      "completion_date": "2020-10-18",
      "has_results": false,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04557397"
    },
    {
      "nct_id": "NCT05720767",
      "title": "HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Lymphoma"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2022-11-04",
      "completion_date": "2023-02-05",
      "has_results": false,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05720767"
    },
    {
      "nct_id": "NCT06291415",
      "title": "The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Immune Thrombocytopenia",
        "Blood Platelet Disorder",
        "Hematologic Diseases",
        "Purpura, Thrombocytopenic",
        "Purpura",
        "Blood Coagulation Disorder",
        "Thrombotic Microangiopathies",
        "Hemorrhagic Disorders",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Hemorrhage",
        "Pathologic Processes",
        "Skin Manifestations",
        "Thrombocytopenia",
        "Purpura, Thrombocytopenic, Idiopathic",
        "Primary Immune Thrombocytopenia",
        "ITP - Immune Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "HMPL-523",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-02",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Georgetown",
          "state": "Delaware"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06291415"
    },
    {
      "nct_id": "NCT05176691",
      "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CLL/SLL",
        "NHL",
        "MCL",
        "MZL",
        "Lymphoplasmacytic Lymphoma",
        "Waldenstrom Macroglobulinemia",
        "Follicular Lymphoma",
        "DLBCL",
        "Richter Syndrome"
      ],
      "interventions": [
        {
          "name": "HMPL-760",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-02-15",
      "completion_date": "2022-11-16",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • Atlanta, Georgia • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05176691"
    },
    {
      "nct_id": "NCT05093322",
      "title": "A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Rhabdomyosarcoma",
        "Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)"
      ],
      "interventions": [
        {
          "name": "Surufatinib in combination with Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-30",
      "completion_date": "2023-04-25",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-06T13:31:22.513Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05093322"
    }
  ]
}